CV Lattes
Universidade Federal de São Paulo (UNIFESP). Campus São Paulo. Escola Paulista de Medicina (EPM) (Institutional affiliation from the last research proposal) Birthplace: Brazil
Bachelor's degree in Biomedical Science, MSc and PhD at Universidade Federal de São Paulo. Experience in translational cancer research, mainly in polymorphism genotyping, gene expression, sequencing, single cell/nuclei transcriptomics, primary cell culture and animal models. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Osteosarcoma (OS) is a malignant bone tumor derived from primitive mesenchymal cells and the most common in children and adolescents. Despite progress in OS treatment in recent decades, it has reached a plateau. The most recent clinical studies, which are focused on improved outcomes, through the intensification of therapy or incorporation of new therapeutic agents, have not been successf…
Osteosarcoma (OS) is the most common malignant bone tumor in children and adolescents. Etiology of this tumor still unknown and drug resistance remains an important factor that affects many patients. The difference in treatment response is due to genetic variability between individuals, which generates differences in the profile of drug metabolizing enzymes, for example. Cytochrome P-450 …
Osteosarcoma (OS) is the most frequent bone tumor in children and adolescents. Despite recent advances in cancer treatment, its progress has reached a plateau. Drug resistance and unfavorable clinical results affect nearly 50% of all patients. Studies looking for changes that may be used as prognostic factors and therapeutic targets, can improve the cure in high-risk patients and minimize…
Osteosarcoma is the most common primary malignant bone tumor affecting children, adolescents and young adults. Patients with localized disease are cured in 65% of patients, but no improvement in prognosis has been seen since the addition of chemotherapy 40 years ago. In order to better understand the biology of osteosarcoma and to develop novel immunotherapies, we propose to use the lates…
| 3 / 3 | Completed scholarships in Brazil |
| 1 / 1 | Completed scholarships abroad |
| 4 / 4 | All Scholarships |
| Associated processes | |